A Study of Olverembatinib in SDH-deficient GIST.

Prior treatment

• Received antitumor cytotoxic chemotherapy, radiotherapy, biologic drug therapy, immunotherapy, or other investigational agents within 14 days or less than 5 times the half-life prior to the first dose.
• Tyrosine kinase inhibitor (TKI) therapy within 7 days prior to the first dose.
• Use of drugs that have drug interactions with the study drug within 7 days prior to the first dose.
• Adverse events due to prior treatment have not recovered (\> NCI CTCAE v5.0 Grade 1).
• Severe cardiovascular and cerebrovascular diseases during previous use of TKIs.
• Major surgery, open biopsy, or major traumatic injury within 14 days prior to initiation of study drug.
• Any symptoms or disease of the patient, in the judgment of the investigator or sponsor, that may jeopardize their safety or interfere with the safety evaluation of the investigational drug.

Other illness

• Absorption disorder syndrome or other conditions that affect the absorption of oral medications.
• With clinically significant, uncontrolled or active cardiovascular disease or thrombotic disease.
• Poorly controlled hypertension after hypertension medication.
• Other malignancies within 2 years.
• Uncontrolled systemic active fungal, bacterial, and/or viral infections.

Other

• Uncontrolled Hyperlipidemia.
• With brain metastases.
• Female patients who are pregnant or lactating, or female patients who are expecting to become pregnant within the period of this study.

• Histologically and/or cytologically confirmed GIST, immunohistochemistry with loss of SDHB expression, and failure of at least one prior systemic therapy. Defined as disease progression or intolerable as judged by the investigator.
• Must have at least one measurable target lesion.
• ECOG≤ 2.
• Expected survival of at least 3 months.
• Adequate organ function.
• Negative serum pregnancy test result for women of childbearing potential within 7 days prior to taking the first dose of study drug.
• Males, women of childbearing potential, as well as their partners, voluntarily take effective contraceptive measures as specified in the protocol from the time of signing the informed consent form until at least 30 days after the last dose of study drug.
• Prior to initiation of any screening or study-specific procedures, the patient or his/her guardian is able to understand and voluntarily sign an informed consent form approved by the Ethics Committee in writing, voluntarily and able to complete the study procedures and follow-up examinations.